| scholarly article | Q13442814 |
| P50 | author | Brian Druker | Q373427 |
| Andreas Hochhaus | Q37829812 | ||
| Leandro Cerchietti | Q39201064 | ||
| Markus Müschen | Q49507635 | ||
| P2093 | author name string | Wolf-Karsten Hofmann | |
| Markus Müschen | |||
| Ari M Melnick | |||
| Neil P Shah | |||
| Melanie Braig | |||
| Eugene Park | |||
| Martin C Müller | |||
| Hassan Jumaa | |||
| Katerina Hatzi | |||
| B Hilda Ye | |||
| Anupriya Agarwal | |||
| Sebastian Herzog | |||
| Yong-mi Kim | |||
| Parham Ramezani-Rad | |||
| Christian Hurtz | |||
| P2860 | cites work | CARF is a novel protein that cooperates with mouse p19ARF (human p14ARF) in activating p53 | Q24303502 |
| The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells | Q24319096 | ||
| A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo | Q27660498 | ||
| Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell | Q27861001 | ||
| DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein | Q28577209 | ||
| The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation | Q28584806 | ||
| Control of inflammation, cytokine expression, and germinal center formation by BCL-6 | Q28585541 | ||
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | Q29614280 | ||
| Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining | Q29614339 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo | Q29619355 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response | Q33561232 | ||
| BCL6 is critical for the development of a diverse primary B cell repertoire | Q33902336 | ||
| c-Myc overexpression uncouples DNA replication from mitosis | Q33958873 | ||
| The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia | Q34099472 | ||
| Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia | Q34157874 | ||
| Gene expression changes associated with progression and response in chronic myeloid leukemia | Q34479561 | ||
| PML targeting eradicates quiescent leukaemia-initiating cells | Q34591761 | ||
| Chronic myeloid leukaemia as a model of disease evolution in human cancer | Q34631354 | ||
| Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. | Q35119075 | ||
| The biology of CML blast crisis | Q35675089 | ||
| Aberrant regulation of hematopoiesis by T cells in BAZF-deficient mice | Q35950048 | ||
| Identification of a tumour suppressor network opposing nuclear Akt function | Q35991130 | ||
| Leukemia stem cells in a genetically defined murine model of blast-crisis CML. | Q36007673 | ||
| The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity | Q36368162 | ||
| Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo | Q36488720 | ||
| CtBP is an essential corepressor for BCL6 autoregulation | Q36498049 | ||
| BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition | Q36684951 | ||
| A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo | Q37157963 | ||
| FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. | Q37598769 | ||
| Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. | Q37626496 | ||
| Targeting leukemic stem cells by breaking their dormancy | Q37769764 | ||
| TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia | Q39744014 | ||
| Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells | Q40228137 | ||
| Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity | Q41356541 | ||
| Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice | Q41779350 | ||
| Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy | Q46217173 | ||
| Stat5a is mandatory for adult mammary gland development and lactogenesis. | Q48055024 | ||
| Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. | Q54581100 | ||
| BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. | Q55034216 | ||
| Awakening dormant haematopoietic stem cells | Q58379701 | ||
| A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia | Q59080605 | ||
| Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow | Q77531813 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| chronic myeloid leukemia | Q729735 | ||
| P304 | page(s) | 2163-2174 | |
| P577 | publication date | 2011-09-12 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia | |
| P478 | volume | 208 |
| Q39017947 | A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells |
| Q90575658 | A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma |
| Q47627255 | Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis |
| Q38057413 | Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop |
| Q36989582 | All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo |
| Q35931271 | Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond |
| Q92424125 | Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma |
| Q55306287 | Apoptosis in inner ear sensory hair cells. |
| Q37949308 | Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks |
| Q47269833 | BCL6 as a therapeutic target for lymphoma |
| Q28829626 | BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy |
| Q40267907 | BCL6 promotes glioma and serves as a therapeutic target. |
| Q38959240 | Bcl-6 directly represses the gene program of the glycolysis pathway |
| Q39852423 | Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory |
| Q47155635 | Bcl6 gene-silencing facilitates PMA-induced megakaryocyte differentiation in K562 cells |
| Q35776432 | Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival |
| Q26748769 | Chronic myeloid leukemia: reminiscences and dreams |
| Q50123249 | Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment |
| Q90262529 | Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit |
| Q38187388 | Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting |
| Q42938924 | Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. |
| Q27025242 | Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q58708831 | Deacetylase activity-independent transcriptional activation by HDAC2 during TPA-induced HL-60 cell differentiation |
| Q64914303 | Deciphering the scalene association among type-2 diabetes mellitus, prostate cancer, and chronic myeloid leukemia via enrichment analysis of disease-gene network. |
| Q99248489 | Declaration of Bcr-Abl1 independence |
| Q64076943 | Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s |
| Q36560517 | Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph(+) leukemia. |
| Q60683708 | Detecting genome-wide directional effects of transcription factor binding on polygenic disease risk |
| Q38392692 | Discontinuation of tyrosine kinase therapy in CML. |
| Q38289033 | Do we need more drugs for chronic myeloid leukemia? |
| Q28276260 | Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells |
| Q48189669 | Emerging Roles of MTG16 in Cell-Fate Control of Hematopoietic Stem Cells and Cancer |
| Q38010385 | Emerging epigenetic targets and therapies in cancer medicine |
| Q37051682 | Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells |
| Q48946028 | Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition |
| Q92409425 | Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML |
| Q38674456 | FOXO transcription factors in cancer development and therapy |
| Q34405336 | FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development |
| Q37709313 | FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma |
| Q42317507 | FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition |
| Q50137602 | FoxO transcription factors in cancer metabolism |
| Q33914049 | Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines |
| Q58845447 | Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design |
| Q92363766 | Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis |
| Q37702652 | Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia |
| Q39022440 | Induction of p53 suppresses chronic myeloid leukemia. |
| Q91614292 | Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia |
| Q51075769 | Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells. |
| Q34106870 | JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. |
| Q38175466 | Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia |
| Q28550350 | Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release |
| Q38118817 | Leukemia stem cells: Old concepts and new perspectives |
| Q53110472 | Loss of Dnmt3b accelerates MLL-AF9 leukemia progression. |
| Q38185576 | Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence |
| Q38602633 | Minimal Residual Disease Eradication in CML: Does It Really Matter? |
| Q26828528 | Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells |
| Q28508595 | Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile |
| Q41085680 | Mtss1 is a critical epigenetically regulated tumor suppressor in CML. |
| Q38392667 | Natural course and biology of CML. |
| Q28550487 | Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells |
| Q52846906 | Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. |
| Q26768158 | Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities |
| Q37554700 | Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression |
| Q91863573 | Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells |
| Q38028778 | Pushing the limits of targeted therapy in chronic myeloid leukaemia. |
| Q34892704 | Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. |
| Q27026031 | Signal transduction in the chronic leukemias: implications for targeted therapies |
| Q97530194 | Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML |
| Q40817591 | Stem cell persistence in chronic myeloid leukemia |
| Q36544358 | Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells |
| Q38069545 | Targeting chronic myeloid leukemia stem cells. |
| Q37122686 | Targeting survival pathways in chronic myeloid leukaemia stem cells |
| Q38002489 | The 1-1-1 fallacy |
| Q39018438 | The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target |
| Q41842515 | The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. |
| Q52620231 | The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells. |
| Q34806728 | The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors |
| Q26749343 | The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase |
| Q26783658 | The role of steroid hormones in breast cancer stem cells |
| Q89835369 | Transcriptional Regulation of Genes by Ikaros Tumor Suppressor in Acute Lymphoblastic Leukemia |
| Q35063947 | Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma |
| Q34401328 | Using functional genomics to overcome therapeutic resistance in hematological malignancies. |
| Q35055094 | miR-127 regulates cell proliferation and senescence by targeting BCL6. |
| Q43249196 | p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. |
Search more.